News

Solid Tumors
Breast Cancer

Preparing for Steep Increase in Breast Cancer Among the Elderly

Charlotte Bath  / December 10, 2017

“We are in the midst of a steep increase” in the incidence of breast cancer among women aged 65 years and older, Arti Hurria, MD, reported at the 19th Annual Lynn Sage Breast Cancer Symposium, Chicago.1 “Are we prepared as a health-care system and as providers to address this burgeoning need?” she a...

Sarcoma
Solid Tumors

NCCN Introduces New Guidelines for Patients With AIDS-Related Kaposi Sarcoma

The ASCO Post  / December 10, 2017

The National Comprehensive Cancer Network® (NCCN®) has created a new resource for patients living with human immunodeficiency virus (HIV) who develop acquired immune deficiency syndrome (AIDS)-related Kaposi sarcoma. This newly released NCCN Clinical Practice Guidelines in Oncology (N...

Issues in Oncology

Experts Address Cancer Health Disparities in Facebook Live Session at AACR Meeting

Meg Barbor, MPH  / November 25, 2017

Although it has long been known that certain cancer types disproportionately affect individuals from underserved and underrepresented populations, the sources of these disparities are still not entirely clear. In a “Facebook Live” session at the 2017 American Association for Cancer Research (AACR) C...

Solid Tumors
Breast Cancer
Issues in Oncology
Health-Care Policy

Health-Care Access Unlikely to Explain Racial/Ethnic Disparities in Breast Cancer Outcomes

Meg Barbor, MPH  / November 25, 2017

Even with equivalent access to care, black patients with breast cancer may fare worse than white patients with breast cancer, according to Lawrence H. Kushi, ScD, Director of Scientific Policy at the Kaiser Permanente Northern California Division of Research in Oakland. “Accounting for socioec...

Solid Tumors
Lung Cancer

Addressing Disparities in Use of Lung Cancer Screening With Community Outreach

Meg Barbor, MPH  / November 25, 2017

African Americans and members of other communities of lower socioeconomic status have higher burdens of lung cancer mortality. Therefore, targeting underserved patient populations with lung cancer screening is of the utmost importance, according to Christopher Lathan, MD, MS, MPH, a medical oncologi...

Genomics/Genetics
Solid Tumors
Lymphoma
Multiple Myeloma

Update on NCI-MATCH Precision Medicine Trial

The ASCO Post  / November 25, 2017

THE NATIONAL CANCER INSTITUTE (NCI) Molecular Analysis for Therapy Choice (MATCH) clinical trial has achieved the goal of screening nearly 6,000 patients in just under 2 years, according to data presented at the 2017 American Association for Cancer Research–NCI–European Organisation for Research and...

Solid Tumors

Early Findings on EZH2 Inhibitor in Children With Rare Solid Tumors

The ASCO Post  / November 25, 2017

CHILDREN WITH relapsed or refractory malignant rhabdoid tumors, epithelioid sarcomas, or poorly differentiated chordomas with a particular genetic defect were treated with the investigational drug tazemetostat and appeared to tolerate treatment well. Some patients had objective and durable resp...

Gastrointestinal Cancer

Positioning 177-Lu-Dotatate Therapy and 68-Ga-Dotatate Scans in Management of Neuroendocrine Tumors

Caroline Helwick  / September 10, 2017

The results of the phase III NETTER-1 trial, recently published in The New England Journal of Medicine,1 have been met with great interest by clinicians who treat neuroendocrine tumors. In patients with advanced midgut lesions, treatment with the radiopharmaceutical lutetium-177-Dotatate (177-Lu-Dot...

Global Cancer Care

First Comprehensive Pediatric Hematology/Oncology Initiative Launched in Africa

The ASCO Post  / July 10, 2017

Through public-private partnerships with the governments of Botswana, Uganda, and Malawi, His Excellency the President Lieutenant General Dr. Seretse Khama Ian Khama, of the Republic of Botswana; the Honorable Minister Dorcas Makgato, of the Ministry of Health and Wellness; the Bristol-Myers Squibb ...

Lung Cancer

The Ongoing Challenges of Lung Cancer Screening

Ronald Piana  / May 25, 2017

Lung cancer persistently remains the leading cause of cancer death among men and women in the United States. Only about 15% of lung cancers are diagnosed at the localized stage, when clinical intervention could markedly improve patient outcomes. For decades, lung cancer specialists and advocacy grou...

Pancreatic Cancer

ESTRO 2017: Study Suggests Role for Radiotherapy in Extending Survival in Patients With Early-Stage Pancreatic Cancer

The ASCO Post  / May 25, 2017  / 43537

Radiotherapy at a high enough dose may increase survival in early-stage pancreatic cancer, according to research presented at the European Society for Radiotherapy & Oncology (ESTRO) 36 Conference.1 Previous research has suggested that radiotherapy may be of little help in this setting. The stu...

Issues in Oncology

Tackling the Obesity and Cancer Epidemic

Jo Cavallo  / May 25, 2017

Research is still lacking to support a link between obesity and an increased risk of developing all types of cancer. Nevertheless, a review1 of more than 1,000 epidemiologic studies by the International Agency for Research on Cancer (IARC), a division of the World Health Organization, examining ...

Bladder Cancer

SWOG Launches First Prospective Registration Trial With Atezolizumab in BCG-Unresponsive Non–Muscle Invasive Bladder Cancer

Parminder Singh, MD  / May 10, 2017

The standard of care for patients with Bacillus Calmette-Guérin (BCG)-unresponsive, high-risk non–muscle invasive bladder cancer is radical cystectomy. Novel therapies that allow patients to preserve their bladder are urgently needed. SWOG (formerly the Southwest Oncology Group),...

Issues in Oncology
Health-Care Policy

Accelerating Pediatric Drug Development: Master Protocols May Be a Way to Go

Margot J. Fromer  / April 25, 2017

Development of pediatric cancer drugs has long lagged behind adult drug development for two major reasons: The process is more difficult, and childhood cancer is rarer by far than adult cancer. These and other phenomena in pediatric oncology were the subject of a workshop held by the ...

Issues in Oncology

Scientists Tackle Next Set of Immunotherapy Challenges

Caroline Helwick  / March 10, 2017

Cancer immunotherapy is about to get much more complicated. Just as oncologists are becoming familiar with checkpoint inhibitors and their growing indications, they will eventually be challenged with using them in novel combinations and in new tumor types. This will be the fruit that comes from unde...

Head and Neck Cancer

Novel Immunotherapy Added to Standard Care Did Not Meet Endpoint in Patients With Advanced Head and Neck Cancer

Caroline Helwick  / March 10, 2017  / 35862

In the phase II Active8 trial, a novel immunotherapy agent, motolimod, failed to improve outcomes over chemotherapy plus cetuximab (Erbitux) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. In a post hoc analysis, however, patients with injection-...

Head and Neck Cancer

Expert Point of View: Cornelius J.M. Melief, MD, PhD

Caroline Helwick  / March 10, 2017

Cornelius J.M. Melief, MD, PhD, Emeritus Professor at Leiden University Medical Center in the Netherlands and Chief Scientific Officer at ISA Pharmaceuticals, noted that toll-like receptors (TLRs) are useful in promoting immune activation in a variety of leukocytes and that the signal...

Cost of Care

Value-Based Approaches to the Rising Costs of Cancer Drugs

Alice Goodman  / March 10, 2017  / 36751

It’s no secret that cancer drug costs have skyrocketed out of control, with some treatments costing as much as $100,000 to $200,000 per year and even upward. This has put tremendous strain on the U.S. health-care system, while causing financial toxicity and bankruptcy for many patient...

Multiple Myeloma

CAR T-Cell Therapy Emerging in Multiple Myeloma

Caroline Helwick  / March 10, 2017  / 36569

For patients with multiple myeloma, chimeric antigen receptor (CAR) T-cell therapy is gaining ground in pilot studies. At the 2016 American Society of Hematology (ASH) Annual Meeting & Exposition, researchers presented their latest findings for this innovative therapy, which has proven beneficia...

Multiple Myeloma

Expert Point of View: Edward A. Stadtmauer, MD

Caroline Helwick  / March 10, 2017

In a lecture at the 2016 American Society of Hematology (ASH) Annual Meeting & Exposition, Edward A. Stadtmauer, MD, Chief of the Hematologic Malignancies Section at the University of Pennsylvania Perelman School of Medicine, Philadelphia, summarized the advances in chimeric antig...

ASCO and NCCN to Collaborate on Guidelines on Management of Immunotherapy Side Effects

The ASCO Post  / March 10, 2017

ASCO and the National Comprehensive Cancer Network® (NCCN®) have announced a joint collaboration to publish practical clinical guidance on the management of side effects caused by immunotherapy. This novel collaboration aims to rapidly support improved quality of care for the growing number of patie...

Hematologic Malignancies

Pacritinib Reduces Spleen Volume in Myelofibrosis

Alice Goodman  / March 10, 2017

The investigational drug pacritinib met the primary endpoint of the phase III PERSIST-2 trial in high-risk patients with myelofibrosis and thrombocytopenia. Treatment with the Janus kinase (JAK)1/2 inhibitor pacritinib achieved a significant reduction in spleen volume compared with best available th...

Expert Point of View: Selina Luger, MD, Stephanie Lee, MD, and Gabriela Hobbs, MD

Alice Goodman  / March 10, 2017

Speaking at the 2016 American Society of Hematology (ASH) Annual Meeting & Exposition, before the hold on pacritinib was lifted (in January 2017), Selina Luger, MD, of the University of Pennsylvania, Philadelphia, commented, “I think the U.S. Food and Drug Administration (FDA) needs to revi...

Leukemia

Phase II Studies Evaluate New Approaches in Richter Transformation

Caroline Helwick  / February 25, 2017

Despite advances in treating chronic lymphocytic leukemia (CLL), the 5% to 10% of patients who develop Richter transformation continue to have poor outcomes. For these patients, median progression-free survival is approximately 6 months, and median overall survival is about 8 months. Phase II studie...

Expert Point of View: Jose Leis, MD, PhD

Caroline Helwick  / February 25, 2017

Jose Leis, MD, PhD, of the Mayo Clinic in Arizona, commented on the promise of checkpoint inhibitors in Richter transformation. “At Mayo, we have treated more than 30 patients with programmed cell death protein 1 (PD-1) blockade. We do see that chronic lymphocytic leukemia (CLL) has low express...

Prostate Cancer

On the Horizon: New Tools for Prostate Cancer

Alice Goodman  / February 10, 2017

The field of prostate cancer is being energized by discoveries in genetics, novel imaging techniques, and the potential of checkpoint inhibitors in the treatment of prostate cancer. Not all of these advances are currently clinically actionable, but all have the potential to change cli...

City of Hope, Translational Genomics Research Institute Combine to Advance Precision Medicine and Speed Translational Research

The ASCO Post  / December 10, 2016

City of Hope and Translational Genomics Research Institute (TGen) have announced an alliance to make precision medicine a reality for patients. This alliance enables both institutes to complement each other in their common areas of research and patient care, with City of Hope providing a significant...

Multiple Myeloma

Genetic Link May Explain Outcomes Differences in Multiple Myeloma in African Americans

Ronald Piana  / December 10, 2016

African Americans are more than twice as likely as their white counterparts to be diagnosed with multiple myeloma, and twice as likely to die from this form of cancer. Research presented at the 9th American Association for Cancer Research (AACR) Conference on the Science of Cancer Hea...

Supportive Care

What’s New in Antiemesis Therapy

Caroline Helwick  / December 10, 2016

The optimal use of new antiemetics was the subject of a presentation at the 14th Annual School of Breast Oncology, Emory University, Atlanta, by Frankie Ann Holmes, MD, Associate Director of Breast Oncology Research at Texas Oncology, Houston. “The science of nausea and vomiting is so...

Issues in Oncology

Disparities of Care: Navigation System Helps Connect Underserved Populations to Cancer Services

Ronald Piana  / December 10, 2016

Although we’ve seen substantial progress in cancer treatment, screening, diagnosis, and prevention over the past decades, certain underserved populations have not reaped the benefits of many of these advances. Turning research into actionable programs in this area was highlighted by a...

NCCN Imaging Appropriate Use Criteria Published for 15 Additional Guidelines

The ASCO Post  / December 10, 2016

The National Comprehensive Cancer Network® (NCCN®), a Centers for Medicare & Medicaid Services (CMS)-approved provider-led entity for imaging appropriate use criteria, continues to build its library of these standards and has published NCCN Imaging Appropriate Use Criteria™ for an additional 15 ...

NCCN Launches Campaign to Eradicate Fatal Vincristine Errors

Caroline McNeil  / December 10, 2016

It is uniformly fatal and impossible to undo. When the chemotherapy drug vincristine is placed in a syringe and injected intrathecally—into the spinal fluid—the patient always dies. And despite safety guidelines and labels, deaths continue to occur. Now the National Comprehensive Cancer Network® (N...

ASCO Releases Criteria for High-Quality Clinical Pathways in Oncology

The ASCO Post  / December 10, 2016

ASCO recently released its Criteria for High-Quality Clinical Pathways in Oncology, a set of 15 interrelated criteria that provide an overarching framework for assessing pathway programs in the United States. ASCO developed the criteria to guide stakeholders in assessing the quality, ...

Bladder Cancer

KEYNOTE-045 Trial Finds Pembrolizumab Improves Survival Over Chemotherapy in Advanced Urothelial Cancer

The ASCO Post  / November 10, 2016

The phase III KEYNOTE-045 trial, investigating the use of the anti–PD-1 (programmed cell death protein 1) therapy pembrolizumab (Keytruda) in patients with previously treated advanced urothelial cancer, met the primary endpoint of overall survival, according to a news release issued b...

Advanced Practitioners Convene for Annual JADPRO Live at APSHO Meeting

The ASCO Post  / November 10, 2016  / 36326

The fourth annual JADPRO Live conference was held recently in conjunction with the Annual Meeting of the Advanced Practitioner Society for Hematology and Oncology (APSHO) on November 3–6, 2016, at the Gaylord National Hotel in National Harbor, Maryland. More than 1,100 indiv...

Health-Care Policy

NIH Expands National Precision Medicine Initiative Cohort Program

The ASCO Post  / October 25, 2016

The National Institutes of Health (NIH) has announced awards to add four regional medical center groups to the national network of health-care provider organizations that will implement the Precision Medicine Initiative Cohort Program. Combined, the new health-care provider organizations will receiv...

The Medicinal Power of Minerals

Jo Cavallo  / October 25, 2016

In September, the National Institutes of Health (NIH), in partnership with the Smithsonian Institution National Museum of Natural History, opened the Minerals in Medicine exhibition at the NIH Clinical Center in Bethesda, Maryland. The exhibition, which includes more than 40 minerals and metals th...

Issues in Oncology

New American Cancer Society Report Reveals Gaps, Identifies Unique Barriers in Pediatric Cancer Research

The ASCO Post  / October 25, 2016

A first-of-its-kind joint report from the American Cancer Society and the Alliance for Childhood Cancer has compiled the latest information related to pediatric cancer, including statistics and trends; a current list of drugs used to treat pediatric cancers; ongoing pediatric cancer c...

Multiple Myeloma

Multiple Myeloma Research Foundation to Donate Data to NCI’s Genomic Data Commons

The ASCO Post  / October 10, 2016

The National Cancer Institute (NCI) recently announced a collaboration with the Multiple Myeloma Research Foundation to incorporate the Foundation’s wealth of genomic and clinical data about the disease into the NCI Genomic Data Commons. NCI’s Genomic Data Commons is a publicly available database th...

Cancer Moonshot Blue Ribbon Panel Recommends 10 Ways to Speed Cancer Advances

Jo Cavallo  / September 25, 2016

Earlier this month, members of the National Cancer Moonshot Initiative’s Blue Ribbon Panel submitted an ambitious list of 10 recommendations on the scientific approaches that are most likely to accelerate progress against cancer to the President’s National Cancer Advisory Board. The panel’s suggesti...

Breast Cancer

Nipple-Sparing Mastectomy Shown to Be Safe—and Increasingly Preferred

Caroline Helwick  / September 10, 2016

Prophylactic mastectomy that preserves a woman’s nipple is oncologically safe in patients with deleterious BRCA mutations, according to the largest study yet to evaluate this approach in this high-risk population. “In more than 500 risk-reducing nipple-sparing mastectomies in 348 dele...

Expert Point of View: Julie ­Margenthaler, MD

Caroline Helwick  / September 10, 2016

The moderator of the press briefing, Julie ­Margenthaler, MD, of Washington University, St. Louis, maintained there are few contraindications for nipple-sparing mastectomy. “I reiterate Dr. Jakub’s view. I agree it’s absolutely safe for BRCA-positive patients,” she declared. The contraindicati...

Epithelial Cells on the Tail Fin of Genetically Engineered Zebrafish

The ASCO Post  / August 10, 2016

Image depicts hundreds of live cells from a tiny bit of skin on the tail fin of a genetically engineered adult zebrafish. The cells have been labeled with a new fluorescent imaging tool called Skinbow. It uniquely color codes cells by getting them to express genes encoding red, green, and blue flu...

Health-Care Policy

Photonics and the Cancer Moonshot Initiative: Partnership Highlights Role of Technology and IT Infrastructure in Reaching Goals

Caroline McNeil  / August 10, 2016

Photonics—the science of light—may not be associated with cancer in most people’s minds. But photonic technologies are: CT (computed tomography) scans and digital x-rays, for instance, are in everyday use, and next-generation oncology applications are in development. As the White House’s National C...

Issues in Oncology

Survey Finds Most Americans Unlikely to Enroll in Clinical Trials

The ASCO Post  / June 10, 2016

According to a new survey of more than 1,500 consumers and nearly 600 physicians conducted for Memorial Sloan Kettering Cancer Center (MSK), only 35% of Americans indicated that they were “likely” to enroll in a clinical trial. Clinical research is increasingly dependent upon larger numbers of cance...

Leukemia

Seattle Children’s Reports Promising Early Results With Immunotherapy in Relapsed ALL

The ASCO Post  / June 10, 2016

Seattle Children’s announced that 39 of 42 patients treated in a phase I clinical trial using genetically reprogrammed T cells to treat relapsed or refractory acute lymphoblastic leukemia (ALL) have achieved complete remission, showing no detectable leukemia cells. Phase II of this trial, known as t...

Pancreatic Cancer

Phase Ib/II Study Reports High Response Rates Seen With Addition of Cisplatin to Regimen for Advanced Pancreatic Cancer

Caroline Helwick  / April 10, 2016

The oncology research team at HonorHealth Research Institute in Scottsdale, Arizona, is spearheading a phase Ib/II trial that is demonstrating promising results with a novel regimen in patients with advanced pancreatic cancer. “The patients we are treating have advanced adenocarcinoma of the ...

Advertisement

Advertisement



Advertisement